Joseph Tucci
Endocrinology, Diabetes & Metabolism · Providence, RINPI 1780641084
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,550 of the $30,193 with a category attached, or 64.8%. Radius Health, Inc. accounts for 73.5% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $20,281 and has fallen 99.4% since, to $121 in 2025.
Across 396 payments — averaging $76.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Radius Health, Inc.$22K
- Amgen$1K
- Lilly USA, LLC$1K
- AbbVie$1K
- Sanofi-aventis U.S. LLC$889
- Bayer$445
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$19,55065%
- Travel & lodging$1,9857%
- Food & beverage$8,61729%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Radius Health, Inc. | 29 | $22,198 |
| Amgen | 48 | $1,367 |
| Lilly USA, LLC | 54 | $1,118 |
| AbbVie | 54 | $1,102 |
| Sanofi-aventis U.S. LLC | 45 | $889 |
| Bayer | 14 | $445 |
| Abbott | 24 | $381 |
| AstraZeneca(2 entities) | 19 | $378 |
| IBSA Pharma Inc. | 19 | $355 |
| Novo Nordisk | 18 | $319 |
| Boehringer Ingelheim | 13 | $277 |
| Corcept Therapeutics | 5 | $216 |
| Xeris Pharmaceuticals, Inc. | 10 | $181 |
| Ultragenyx Pharmaceutical Inc. | 5 | $180 |
| Eisai Inc. | 5 | $111 |
| Medtronic(2 entities) | 4 | $106 |
| Shire North American Group Inc | 5 | $100 |
| Dexcom, Inc. | 4 | $66 |
| Regeneron Healthcare Solutions, Inc. | 4 | $64 |
| Sun Pharmaceutical Industries Inc. | 3 | $57 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Mannkind Corporation | 2 | $46 |
| Cequr Corporation | 1 | $39 |
| Companion Medical, Inc. | 2 | $37 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
| EUSA Pharma (US) LLC | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Circassia Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,193 in reported general payments places this provider in the 80th percentile of 30 endocrinology, diabetes & metabolism providers in Rhode Island.
See all endocrinology, diabetes & metabolism providers in Rhode Island →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 21 | $25,963 |
| KerendiaFinerenone | 13 | $13,318 |
| TrulicityDulaglutide | 11 | $12,118 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $11,992 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $2,875 |
| SynthroidLevothyroxine Sodium | 23 | $2,862 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 28 | $2,013 |
| Levothyroxine Sodium | 98 | $1,021 |
| Rosuvastatin Calcium | 31 | $855 |
| Alendronate Sodium | 22 | $344 |
| Glimepiride | 16 | $186 |
| Glipizide | 27 | $174 |
| Atorvastatin Calcium | 25 | $140 |
| Metformin Hcl | 11 | $95 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $277 | $25,96321 claims |
| BayerKerendia | $445 | $13,31813 claims |
| Lilly USA, LLCTrulicity | $1,118 | $12,11811 claims |
| AbbVieSynthroid | $1,102 | $2,86223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 30 endocrinology, diabetes & metabolism providers in Rhode Island.
Other endocrinology, diabetes & metabolism in Providence
- Robert DobrzynskiProvidence$245K
- Robert SmithProvidence$80K
- Manchin ChangProvidence$878
- Roberto OrtizProvidence$598
- Daryl SelenProvidence$450
- Alicia WarnockProvidence$317
- Meghana KoletiProvidence$145
- Charles KahnProvidence$125
- David MacleanProvidence$121
- Frank D'alessandroNorth Providence$193K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.